key: cord-1046946-aixxdxm8
authors: Basile, Kerri; McPhie, Kenneth; Carter, Ian; Alderson, Susan; Rahman, Hossinur; Donovan, Linda; Kumar, Shanil; Tran, Tyna; Ko, Danny; Sivaruban, Tharshini; Ngo, Christine; Toi, Cheryl; O’Sullivan, Matthew V; Sintchenko, Vitali; Chen, Sharon C-A; Maddocks, Susan; Dwyer, Dominic E; Kok, Jen
title: Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19
date: 2020-10-24
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1579
sha: d4e8336c4b1582f652abfa44b358babe6efd9792
doc_id: 1046946
cord_uid: aixxdxm8

BACKGROUND: The detection of SARS-CoV-2 RNA by real-time polymerase chain reaction (PCR) in respiratory samples collected from persons recovered from COVID-19 does not necessarily indicate shedding of infective virions. By contrast, the isolation of SARS-CoV-2 using cell-based culture likely indicates infectivity, but there are limited data on the correlation between SARS-CoV-2 culture and PCR. METHODS: One hundred and ninety-five patients with varying severity of COVID-19 were tested (outpatients [n=178]), inpatients [n=12] and critically unwell patients admitted to the intensive care unit [ICU; n=5]). SARS-CoV-2 PCR positive samples were cultured in Vero C1008 cells and inspected daily for cytopathic effect (CPE). SARS-CoV-2-induced CPE was confirmed by PCR of culture supernatant. Where no CPE was observed, PCR was performed on day four to confirm absence of virus replication. Cycle threshold (Ct) of the day four PCR (Ct(culture)) and the PCR of the original clinical sample (Ct(sample)) were compared, and positive cultures were defined where Ct(sample) - Ct(culture) was ≥3. FINDINGS: Of 234 samples collected, 228 (97%) were from the upper respiratory tract. SARS-CoV-2 was only successfully isolated from samples with Ct(sample) ≤32, including in 28/181 (15%), 19/42 (45%) and 9/11 samples (82%) collected from outpatients, inpatients, and ICU patients, respectively. The mean duration from symptom onset to culture positivity was 4.5 days (range 0-18). SARS-CoV-2 was significantly more likely to be isolated from samples collected from inpatients (p<0∙001) and ICU patients (p<0∙0001) compared with outpatients respectively, and in samples with lower Ct(sample). CONCLUSION: SARS-CoV-2 culture may be used as a surrogate marker for infectivity and inform de-isolation protocols.

In late December 2019, a cluster of pneumonia cases of unknown etiology were reported in Hubei Province, China [1] . The causative agent, a novel betacoronavirus, now known as SARS-CoV-2, was isolated on January 7, 2020 [2] and the genetic sequence January 10, 2020 enabling the rapid development of diagnostic assays for COVID-19 (the disease caused by SARS-CoV-2) to be available within a month of the outbreak's notification to the World Health Organization (WHO) *3+. Effective control of SARS-CoV-2 transmission requires widespread testing, isolation, contact tracing of infected persons and other non-pharmaceutical interventions [4] , particularly in the absence of effective SARS-CoV-2-specific antivirals and vaccines. Nucleic acid testing such as real-time reverse transcriptase polymerase chain reaction (PCR) is the predominant diagnostic method to confirm infection, however, the detection of SARS-CoV-2 RNA may not always indicate the presence or shedding of viable virus with replicative capacity and, by implication, transmissibility [5] . The diagnostic value of culture in the routine management of COVID-19 is limited by requirements of isolation to be performed under physical containment laboratory level 3 (PC3) biosafety conditions [6] , technical expertise, turnaround times (TATs), and costs. However, the ability to culture SARS-CoV-2 has important roles in providing adequate positive control material for the development, validation, evaluation and quality assurance of SARS-CoV-2 diagnostic assays; supporting the development of vaccines and therapeutic agents, and enabling research into viral virulence and transmission.

Despite clinical recovery, there are a proportion of patients where SARS-CoV-2 RNA remains detectable for many days to weeks [5] . The relationship between persistent PCR positivity and virus viability is important in understanding the natural history and pathogenesis of SARS-CoV-2 infection, and whether truly persistent infection occurs. This has significant implications for the release of infected persons from quarantine, particularly for those who reside in high-risk settings such as aged care, mental health and correctional facilities, or work with at-risk population groups such as A c c e p t e d M a n u s c r i p t 4 healthcare workers (HCWs). Persistent SARS-CoV-2 RNA detection also has implications for patient isolation and bed management, the safe use of non-invasive ventilation and ongoing requirements for appropriate use of personal protective equipment for HCWs when caring for such patients.

We investigated the correlation between SARS-CoV-2 culture and PCR results from respiratory tract samples collected from persons with COVID-19 to guide the safe de-isolation of those with persistently positive PCRs.

April 22, 2020 were analysed. Samples were inoculated into cell culture as part of (i) routine laboratory protocol at the start of the epidemic; (ii) if collected from patients admitted to the ICU and (iii) if requested by attending physicians (usually due to persistent PCR positivity in an individual awaiting release from quarantine) or public health physicians as part of outbreak investigations.

Samples were collected from the upper respiratory tract (URT; nasopharyngeal swabs and combined nose and throat swabs) and lower respiratory tract (LRT; sputum, endotracheal aspirate, nonbronchoscopic bronchoalveolar lavage). URT swabs were received in 1-3 mL of viral or universal transport media (UTM), Amies transport media, or dry; stored at +4°C and tested within 12 hours of specimen receipt. and consumables influenced the targets tested. The total number of samples tested per target were: one (n=24), two (n=115), three (n=22), four (n=62) and five targets (n=11).

Samples with detectable SARS-CoV-2 RNA were inoculated into cell culture under PC3 conditions [4] on the same day or stored at +4°C for inoculation the following day. Vero C1008 (Vero 76, clone E6, A c c e p t e d M a n u s c r i p t 6 Where CPE was observed (generally within 2-3 days post-inoculation), SARS-CoV-2 replication was confirmed by PCR. Terminal sampling and PCR testing of culture supernatant was performed on day 4 as CPE may not be observed despite active viral replication, as seen with SARS-CoV [7] . Day 4 was chosen for terminal sampling as this was the optimal time for reading the endpoint as determined by the 50% tissue culture infective dose (TCID 50 ) assay below. Additionally, with no medium change and using a concentration of amphotericin B (2.5g/mL), cell monolayer breakdown was observed from day 5 onwards in some cultures. instructions. SARS-CoV-2 PCR was then performed as above.

A primary isolate, SARS-CoV-2/01/Human/NSW Australia|EPI_ISL_407893|2020-01-24 (GISAID), was titrated in serial one log dilutions (from 10 -1 to 10 -8 ) to obtain a TCID 50 using 24-well culture plates of Vero C1008 cells. The plates were observed daily for CPE using an inverted optical microscope for five days, and wells were considered positive if any characteristic altered cell foci were seen ( Figure   4 , Supplementary). The end-point titres were calculated according to the Reed and Muench method [8] based on four replicates for titration, and the infectious virus titre of our SARS-CoV-2 stock was 1 x 10 6.5 infectious particles per 200µL (Figure 1 ).

To clarify the significance of the Ct of culture supernatant in the absence of CPE, a dilutional series of 

Welch's t-test, two-tailed hypothesis with 95% confidence intervals (95% CI) was used to compare the mean Ct of URT and LRT samples ( dilutions, and incorporating a 1 log margin of error, we were confident that any clinical sample with a Ct of ≥37 was not indicative of viable virus (Figure 1 ). SARS-CoV-2 was significantly more likely to be isolated in inpatients compared to outpatients (45% vs 15%, p<0•001), and ICU compared with other inpatients (82% vs 45%, p=0•04) or outpatients (82% vs 15%, p<0•001) ( Table 1) In clinical samples where SARS-CoV-2 was isolated, the mean duration between symptom onset and sample collection was 4•5 days (median 3•5, range 0-18). By contrast, the mean duration between symptom onset and sample collection in culture negative samples was 20 days (median 18•4, range 3-29; p<0•001) (Figure 7, Supplementary) .

Detection of SARS-CoV-2 RNA by PCR has been the primary diagnostic method to confirm COVID-19.

As an indicator of infectivity, the absence of detectable SARS-CoV-2 RNA in respiratory tract samples is utilized in many jurisdictions as a requirement for release of persons with COVID-19 from quarantine [10] . In Australia, infected persons from high-risk settings (including but not limited to HCWs) are required to have two consecutive negative SARS-CoV-2 tests at least 24 hours apart A c c e p t e d M a n u s c r i p t 10 before being allowed to return to such settings [11] . Whilst there are reports of persistent or prolonged PCR positive results in recovered persons [12, 13] , few have provided robust data to support that they are no longer infectious. Furthermore, there is substantial variability in the duration of PCR positivity (up to 28 days after symptom onset) [12] , resulting in individuals (including HCWs) being isolated for prolonged periods given the potential risks of virus transmission. As the detection of SARS-CoV-2 RNA in respiratory samples does not necessarily indicate viable infectious virions, we examined the correlation between the Ct of PCR positive samples and viral culture, a surrogate marker for infectivity. The Australian National Guidelines for Public Health Units also recommends that viral culture results be considered when deciding on the release of persons from quarantine following COVID-19 [11] .

We successfully isolated SARS-CoV-2 from upper and lower respiratory tract samples collected from persons with acute COVID-19 and correlated the yield of cell culture with PCR Ct values. Similar to other reports [14, 15] we demonstrate that the threshold Ct where culture will be successful is <32 for the N gene target. However, this Ct is specific for our laboratory and we would recommend that diagnostic laboratories correlate their Ct values with culture results due to the variable analytical performance between different SARS-CoV-2 PCR assays [16, 17] .

The cell culture method described herein relies not only on detection of CPE but incorporates PCR testing into the workflow. We demonstrate that virus with replicative capacity can be isolated and detected despite the absence of CPE by correlating the Ct of cell culture supernatant with the Ct of the original clinical samples where SARS-CoV-2 was detected. This effect was not due to any SARS-CoV-2 genotypes, however further genetic analysis may be warranted. This provides a more objective and sensitive measure of virus isolation as the detection of CPE can be subtle or absent due to low levels of virus that result in a delayed rise in virus load beyond day four in the cell lines used. This may assist in improving workflows in laboratories processing large numbers of cell A c c e p t e d M a n u s c r i p t 11 cultures or those with reduced capacity to detect CPE. A Ct sample cut-off >32 in our laboratory correlates with non-viable virus; and in the absence of CPE, a Ct sample -Ct culture value <3 also indicates an absence of viral replication, suggesting these individuals could be safely released from isolation.

We have demonstrated that culture yield is improved when samples are collected as close to the date of symptom onset as possible, and that virus isolation is more likely in patients with more severe illness requiring admission to hospital or the ICU compared to outpatients. A previous study determined that virus may be isolated up to six days prior to symptom onset [18] , however our study did not include such a cohort. Given the TATs , culture results of samples collected from persons during the pre-symptomatic stage would not be available in a meaningful timeframe to guide clinical management but would provide laboratory evidence of pre-symptomatic or asymptomatic SARS-CoV-2 transmission. We showed culture positivity out to 18 days post-symptom onset in one patient, which is ten days longer than previous findings from Singapore [15] . As paired URT and LRT samples were not collected concurrently in this study, we were not able to ascertain the relationship between the two in the context of de-isolation assessments. In the majority of persons that have clinically recovered from COVID-19, LRT samples may not be available, particularly in the absence of sputum production.

We did not assess whether SARS-CoV-2 replication in the absence of CPE occurs in cell lines other than Vero C1008 cells, However, this has been described in MEK and COS cell lines during the isolation of SARS-CoV [7] . The culture-positive samples demonstrating no CPE but detectable virus replication by PCR were predominantly seen in the ICU cohort with approximately half collected from the LRT. Given the small sample size we were unable to determine whether other factors (e.g. concurrent infections, antimicrobial use) may have affected detection of CPE in these samples. Due to the limited volume of clinical sample received, culture was not set up in duplicate however quality A c c e p t e d M a n u s c r i p t 12 control to ensure the sensitivity of the cells was undertaken with a stock of titred virus to ensure a consistent LoD was maintained.

The performance of our inhouse SARS-CoV-2 assay was comparable to the Roche cobas ® SARS-CoV-2 (Roche Diagnostics, Rotkreuz, Switzerland), (data not shown). Due to reagent shortages, not all samples or culture supernatants were able to be tested with all five SARS-CoV-2 gene targets (E, RdRp, M, N and ORF1ab). Nevertheless, we hypothesize that the findings using the N target would be similar for the other targets as a similar pattern was observed where testing of multiple targets were performed (Figure 2 ). Nucleic acid extraction from the primary sample and culture supernatant was performed on the MagNA Pure 96 and EZ1 Advanced XL instruments, respectively. Previous evaluations of automated nucleic acid extraction instruments for non-SARS-CoV-2 respiratory viruses showed superiority of the EZ1 Advanced XL compared to the MagNA Pure 96 [19] , but there are limited data on the performance of extraction instruments for SARS-CoV-2. We were unable to ascertain if different swab types or UTM affected either PCR or culture results. This study also did not investigate why certain individuals shed SARS-CoV-2 RNA for longer periods compared to others, nor were we able to determine whether there were any factors such as immunosuppression that may have explained prolonged viral shedding, and further research is recommended to address these questions.

In summary, viral culture may assist clinicians to release from isolation individuals who have recovered clinically but remain persistently or intermittently positive SARS-CoV-2 by PCR. Whilst there is limited availability of cell culture in most clinical diagnostic laboratories, this capacity adds important insights not provided by molecular methods and should be maintained in reference laboratories to guide clinical management and de-isolation. 

Geneva: WHO; 2020

Novel coronavirus (2019-nCoV) situation report -1 21

Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe

Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon

Laboratory biosafety guidance related to coronavirus disease (COVID-19)

SARS-associated coronavirus replication in cell lines

A simple method of estimating fifty per cent endpoint

Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling

De-isolating Coronavirus Disease 2019 suspected cases: a continuing challenge

PHLN) joint statement. Revisions to the Australian criteria for release from isolation and return to high-risk settings for persons recovering from COVID-19

Virological assessment of hospitalized patients with COVID-2019

Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

Period of Infectivity to inform strategies for de-isolation of COVID-19 patients

Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit

Interpret with caution: an evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Comparison of commercial systems for extraction of nucleic acids from DNA/RNA respiratory pathogens

We thank Jimmy Ng 1 

A c c e p t e d M a n u s c r i p t 15 A c c e p t e d M a n u s c r i p t 16 A c c e p t e d M a n u s c r i p t 18